Induction Chemotherapy clinical trials

Two versus three chemo treatments before radiation for nasopharyngeal cancer

This Phase 3 trial compares giving two cycles versus three cycles of chemotherapy before other treatment for locally advanced nasopharyngeal cancer. It may help find which schedule works best to control the cancer while managing side effects.

Chemotherapy comparison for advanced nasopharyngeal cancer

This trial compares two different chemotherapy combinations given before radiation for nasopharyngeal cancer. It is for patients with advanced but not metastatic disease who are in good overall health.

Shorter chemo plus immunotherapy for advanced nasopharyngeal cancer

This trial tests a shorter course of chemotherapy combined with an immunotherapy drug (camrelizumab) for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if this approach works well while reducing treatment side effects.

Toripalimab with chemo for advanced nasopharyngeal cancer

This trial tests adding toripalimab (an immunotherapy) to two different platinum-based chemotherapy regimens as initial treatment for locally advanced nasopharyngeal carcinoma. The goal is to see if this combination is more effective than standard treatment.

Comparing two treatment plans for advanced anal cancer

This trial tests if giving chemotherapy before standard chemoradiation works better than standard chemoradiation alone for people with locally advanced anal cancer that has not spread. It aims to improve treatment outcomes.

An Exploratory Study on the Efficacy and Safety of Enlonstobart Combined With Concurrent Radiotherapy and Chemotherapy Following Induction Therapy With Enlonstobart Plus Chemotherapy in Patients With Locally Advanced Cervical Cancer.

Reduced radiation after chemo-immunotherapy for high-risk nasopharyngeal cancer

This trial tests whether a lower dose of radiation, with or without additional chemo-immunotherapy, works as well as the standard full-dose chemoradiation for people with advanced nasopharyngeal cancer who had a complete response after initial chemo-immunotherapy.

Immunotherapy with modified radiation for advanced NPC

This trial tests a new way to give radiation therapy after immunotherapy and chemotherapy for people with advanced nasopharyngeal cancer (NPC) that has partially shrunk. It aims to see if a different radiation schedule works better and has fewer side effects.

Lower radiation dose study for advanced nasopharyngeal cancer

This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.

Toripalimab plus chemo for advanced cervical cancer

This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.

Comparing radiation types for nasopharyngeal cancer

This trial compares two types of radiation therapy (IMRT or IMPT plus CIRT) to see which works better for patients with nasopharyngeal cancer that hasn't spread. It's for people who have not had radiation to the head or neck before.

Tests two ways of treating locally advanced nasopharyngeal cancer

This phase 3 trial compares a standard treatment plan (CRT) versus a new approach (ICCRT) for people with locally advanced nasopharyngeal cancer, without spread to distant organs. It aims to see which plan works better and is safe for tumors in the head and neck area.

Higher-dose proton therapy for stage III lung cancer

This trial tests whether giving a higher dose of a special, precise form of radiation (proton therapy) to the main tumor can improve outcomes for people with stage III lung cancer who are already scheduled for chemoradiation and immunotherapy. It may help by targeting the tumor more effectively while protecting nearby organs.

Pulsed low-dose radiation vs standard chemoradiation for esophageal cancer

This trial compares a new way of giving radiation (in short, pulsed low-dose bursts) to the standard method, both combined with chemotherapy, for people with esophageal cancer. It aims to see if the pulsed approach is safer and equally effective.

Chemo-Immunotherapy Plus Radiation vs Standard Treatment for Advanced Esophageal Cancer

This trial compares two treatment approaches for advanced esophageal squamous cell carcinoma (a type of cancer that starts in the lining of the food tube). One group receives chemotherapy combined with an immunotherapy drug before radiation; the other receives chemotherapy and radiation at the same time. The goal is to see which approach works better.

Cadonilimab plus chemo and radiation for advanced cervical cancer

This trial tests a new immunotherapy drug, cadonilimab, combined with standard chemotherapy followed by chemoradiation for locally advanced cervical cancer. The goal is to see if this combination works better than current treatments.

Chemo before surgery for rectal cancer with liver spread

This trial tests if giving FOLFIRINOX chemotherapy first can improve outcomes for people with rectal cancer that has spread to the liver but can still be removed by surgery.

Chemotherapy and transplant for adult acute myeloid leukemia

This trial tests a combination of chemotherapy and stem cell transplant for adults with acute myeloid leukemia (AML) that is not a specific subtype called APL. It aims to see if this approach is more effective than standard treatments.

Immunotherapy plus chemotherapy for newly diagnosed B-cell leukemia

This trial tests a combination of immunotherapy (using the immune system to fight cancer) and chemotherapy in adults aged 15–65 with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL), a blood cancer. The goal is to see if this combination helps patients achieve remission and survive longer.

Testing chemotherapy with or without extra cancer medicines for nasopharyngeal cancer

This Phase 2 study compares standard chemotherapy (gemcitabine plus cisplatin) against the same chemotherapy plus pembrolizumab and bevacizumab. It aims to see which combination works better for EBV-positive nasopharyngeal cancer before any prior treatment.

Adding Naxitamb to high-risk neuroblastoma treatment

This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.

Treating bile duct cancer with chemo plus Y-90 radiation

This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.

Study of a new drug with chemotherapy for limited-stage small cell lung cancer

This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.

Immunotherapy vs Chemotherapy for Advanced NK/T-cell Lymphoma

This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.